

CORRECTION

Open Access



Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

M. T. Driessen¹, J. Whalen², B. Seewoodharry Buguth², L. A. Vallejo-Aparicio³, I. P. Naya⁴, Y. Asukai^{1*}, B. Alcázar-Navarrete⁵, M. Miravittles⁶, F. García-Río⁷ and N. A. Risebrough⁸

Correction to: *Respir Res*

<https://doi.org/10.1186/s12931-018-0916-7>

Following publication of the original article [1], we have been notified of the below corrections to the 5th paragraph in the Discussion section.

- Reference 24 needs to be amended to 25
- The 12-week study needs to be corrected to 8-week study

Corrected text:

This study is the first to compare two LAMA/LABA dual therapies using direct head-to-head data from a randomized, 8-week study [25], which is the most reliable set of data to include within a cost-effectiveness model [25].

Author details

¹Value Evidence and Outcomes, GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK. ²ICON Health Economics, ICON plc, Abingdon, UK. ³Departamento de Evaluación de Medicamentos, GSK, Tres Cantos, Madrid, Spain. ⁴Global Respiratory Franchise, GSK, Brentford, Middlesex, UK. ⁵Hospital de Alta Resolución de Loja, Granada, Spain. ⁶Pneumology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. ⁷Hospital Universitario La Paz-IdiPAZ, Madrid, Spain. ⁸ICON Health Economics, ICON, Toronto, ON, Canada.

Received: 16 January 2019 Accepted: 16 January 2019
Published online: 28 January 2019

Reference

1. Driessen, et al. Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. *Respir Res.* 2018;19:224. <https://doi.org/10.1186/s12931-018-0916-7>.

* Correspondence: yumiko.x.asukai@gsk.com

¹Value Evidence and Outcomes, GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK

Full list of author information is available at the end of the article

